Open, Prospective, Multi-Center, Two-Part Study of Patient Preference with Monthly Ibandronate Therapy in Women with Postmenopausal Osteoporosis Switched From Daily or Weekly Alendronate or Risendronate-BONCURE: Results of Turkish Sub-Study


Creative Commons License

Eskiyurt N., Irdesel J., Sepici V., Ugurlu H., KİRAZLI Y., ARDIÇ F., ...Daha Fazla

TURK OSTEOPOROZ DERGISI-TURKISH JOURNAL OF OSTEOPOROSIS, cilt.18, sa.1, ss.1-7, 2012 (ESCI) identifier identifier

Özet

Aim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly ibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate.